Clinical trials: Advanced Parkinson's Disease
Parkinson's Disease (PD)
An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease
Parkinson's disease (PD) is a neurological condition, which affects the brain. Some symptoms of PD are tremors, stiffness, and slowness of movement.
- Trial name
- NCT05916157
- Where
- 17 sites in Japan
- Volunteers
- 250 people
- Sponsor
- AbbVie
Parkinson Disease
Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease
Assessment of daily maintenance dose of Sifrol®, L-dopa sparing effect, effect on tremor, depression, anhedonia and tolerability
- Trial name
- NCT02248220
- Testing
- Pramipexole
- Volunteers
- 657 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
Effectiveness of Intensive Rehabilitation in Advanced Stages of Parkinson's Disease.
this study is aimed to evaluate the effectiveness of an Multidisciplinary Intensive Rehabilitation Treatment in Advanced Stages of Parkinson's Disease.
- Trial name
- NCT02731170
- Testing
- MIRT
- Where
- Italy
- Volunteers
- 439 people
- Sponsor
- Ospedale Generale Di Zona Moriggia-Pelascini
Parkinson's Disease
A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients
The primary objective of this study is to investigate safety of SPM 962 in advanced PD patients in a multi-center, open-label, non-controlled study following once-daily multiple transdermal doses of SPM962 within a range of 4.5…
- Trial name
- NCT01631812
- Testing
- SPM 962
- Where
- 7 sites in Japan
- Volunteers
- 130 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Parkinson Disease
PF 06412562 in Subjects With Advanced Stage Parkinson's Disease
The purpose of this study is to test the safety and tolerability of the investigational drug PF-06412562 compared to the current medical standard of care medication for Parkinson's disease, carbidopa/levodopa.
- Trial name
- NCT03665454
- Testing
- PF-06412562
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Milton S. Hershey Medical Center
Parkinson's Disease
A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients
To investigate the safety of once-daily repeated transdermal administration of SPM 962 within a dose range of 4.5 to 36.0 mg/day (54-week treatment period) in Parkinson's disease (PD) patients treated concomitantly with L-dopa in…
- Trial name
- NCT01631825
- Testing
- SPM 962
- Where
- 8 sites in Japan
- Volunteers
- 321 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.